NeurMedix

NeurMedix is a clinical-stage biopharmaceutical company dedicated to developing products for the treatment of neurological and neurodegenerative diseases as well as certain oncological conditions. NeurMedix's leading clinical candidate, NE3107, is a small molecule, oral, anti-inflammatory, insulin sensitizer with a novel mechanism of action, currently in pivotal Phase 3 clinical trials for the treatment of mild to moderate Alzheimer's disease. NeurMedix has invested nearly $100 million in the development of NE3107. Clinical trials for Parkinson’s disease, multiple myeloma, and prostate cancer by NeurMedix are also planned to begin in 2021.